Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Otamixaban dose-ranging study versus unfractionated heparin plus eptifibatide in non-ST elevation acute coronary syndrome
2006-000506-22Phase 2Completed
- Sponsor
- Sanofi
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial of otamixaban in non–ST-segment elevation acute coronary syndrome (NSTE-ACS) (6 arms), sponsored by Sanofi. Primary endpoint: Primary efficacy composite endpoint. Started Feb 2006; status: completed.
02
Drugs
otamixaban
03
Conditions
non–ST-segment elevation acute coronary syndrome (NSTE-ACS)
Beyond the preview
Go deeper on 2006-000506-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000506-22.